Answers are grounded in this paper and cite their sources.
Background Exocrine pancreatic insufficiency is caused by insufficient secretion or limited activity of pancreatic enzymes leading to inadequate food digestion. Consequently, patients with exocrine pancreatic insufficiency develop gastrointestinal symptoms such as diarrhea, abdominal pain, and malnutrition. Pancreatic enzyme replacement therapy enhances fat digestion and absorption, improving the nutritional status and quality of life of these patients. Commonly used oral porcine enzymatic supplements are pH sensitive, with optimal activity restricted to the small intestine. Instead, fungal supplements are also stable in the acidic gastric environment, prolonging enzyme activity duration. Methods The lipolytic efficacy of fungal lipase was compared to porcine lipase under severe pancreatic insufficiency conditions simulated in the tiny-TIM sg dynamic in vitro gastrointestinal model. Results Oral administration of capsules containing 14.000 fungal lipase units (Nortase) led to similar lipid digestion compared to 20.000 porcine lipase units (Kreon and Pangrol) in the tiny-TIM sg dynamic gastrointestinal (GI) in vitro model. Additionally, opening the Nortase capsules and administering its powder content, to simulate administration in patients unable to swallow whole capsules, had no negative effect on fungal lipase activity. Conclusion This work demonstrates in a GI in vitro model, that fungal enzymatic supplements, administered as capsules or powder, have comparable lipid digestion as traditional porcine supplements and, thereby, might be used as an alternative treatment in patients with exocrine pancreatic insufficiency.
No takes yet. Share an insight, caveat, or question.
Garcia et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: